

Ralph T. Kubo, *et al.*  
Serial No.: 08/452,843  
Page 2

B1 In the column that sets forth the source of the peptide, please enter "Plasmodium falciparum SHEBA 77-85".

IN THE CLAIMS:

Please amend Claims 1-2 as follows.

B2 1. (amended) A composition comprising [an immunogenic peptide having a supermotif which allows the immunogenic peptide to bind more than one HLA molecule, the immunogenic peptide having between about 9 and about 10 residues

a first conserved residue at the second position from the N-terminus being P; and

a second conserved residue at the C-terminal position being selected from the group consisting of M, I, and an aromatic residue.] a peptide selected from any one of SEQ ID NOs: 1-21 and SEQ ID NO: 30.

2. (amended) The composition of Claim 1, wherein [the immunogenic peptide is selected from the group consisting of SEQ ID Nos. 1-21] said peptide has the sequence SEQ ID NO: 30.

Please delete Claim 3. Please enter Claims 4-15.

B3 -- 4. A composition of Claim 1, wherein said composition further comprises an additional peptide.

5. A composition of Claim 4, wherein said additional peptide is directly or indirectly linked to a peptide selected from any one of SEQ ID NOs. 1-21 and SEQ ID NO: 30.

6. A composition of Claim 4, wherein said additional peptide is a helper peptide.

7. A composition of Claim 6, wherein said helper peptide has a sequence selected from a group consisting of tetanus toxoid residues 830-843, influenza virus residues 307-319, and malaria circumsporozoite residues 382-398 and 378-389.

8. A composition of Claim 4, wherein said additional peptide is selected from any one of SEQ ID NOs. 1-21 and SEQ ID NO: 30.

9. A composition of Claim 8, wherein one or more such additional peptides are covalently bound to said peptide.

10. A method of inducing in a patient a cytotoxic T cell response against an infectious agent or cancer antigen, the method comprising:

contacting cytotoxic T cells of a patient with a peptide selected from the group consisting of peptides having any one of SEQ ID NOs. 1-21 and SEQ ID NO: 30.

11. A method of Claim 10, wherein said peptide is contacted with said cytotoxic T cells in the presence of an additional peptide.

12. A method of Claim 11, wherein said additional peptide is directly or indirectly linked to said peptide having any one of SEQ ID NOs. 1-21 and SEQ ID NO: 30.

13. A method of Claim 11, wherein said additional peptide is a helper peptide.

14. A method of Claim 13, wherein said helper peptide has a sequence selected from the group consisting of tetanus toxoid residues 830-843, influenza virus residues 307-319, and malaria circumsporozoite residues 382-398 and 378-389.

15. A method of Claim 11, wherein said additional peptide is selected from the group of peptides having any one of SEQ ID NOs. 1-21 and SEQ ID NO: 30. --